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Abstract
Background: Chronic renal disease (CKD) is characterized by complex changes in cell
metabolism leading to an increased production of oxygen radicals, that, in turn has been suggested
to play a key role in numerous clinical complications of this pathological condition. Several reports
have focused on the identification of biological elements involved in the development of systemic
biochemical alterations in CKD, but this abundant literature results fragmented and not exhaustive.
Results: To better define the cellular machinery associated to this condition, we employed a high-
throughput genomic approach based on a whole transcriptomic analysis associated with classical
molecular methodologies. The genomic screening of peripheral blood mononuclear cells revealed
that 44 genes were up-regulated in both CKD patients in conservative treatment (CKD, n = 9) and
hemodialysis (HD, n = 17) compared to healthy subjects (HS, n = 8) (p < 0.001, FDR = 1%).
Functional analysis demonstrated that 11/44 genes were involved in the oxidative phosphorylation
system. Western blotting for COXI and COXIV, key constituents of the complex IV of oxidative
phosphorylation system, performed on an independent testing-group (12 healthy subjects, 10 CKD
and 14 HD) confirmed an higher synthesis of these subunits in CKD/HD patients compared to the
control group. Only for COXI, the comparison between CKD and healthy subjects reached the
statistical significance. However, complex IV activity was significantly reduced in CKD/HD patients
compared to healthy subjects (p < 0.01). Finally, CKD/HD patients presented higher reactive
oxygen species and 8-hydroxydeoxyguanosine levels compared to controls.
Conclusion: Taken together these results suggest, for the first time, that CKD/HD patients may
have an impaired mitochondrial respiratory system and this condition may be both the
consequence and the cause of an enhanced oxidative stress.
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Chronic kidney disease (CKD) is characterized by a pro-
gressive deterioration of renal function. CKD is a common
condition that, according to the recent report of NHANES
III, affects 7.7% of the US population [1]. Recently, an
international consensus categorized CKD into five stages
according to the glomerular filtration rate [2]. The reduc-
tion of renal function, particularly in the more advanced
stages, has been associated to significant changes in
energy metabolism, nitrogen balance, protein-energy
malnutrition and insulin resistance and with a significant
increase in the generation of reactive oxygen species [3-5].
Although many of these biochemical alterations can be
improved by renal replacement treatments, including
hemodialysis (HD) and peritoneal dialysis, these proce-
dures do not reconstitute the normal body homeostasis
[6]. In fact, it has been extensively reported that patients
in renal replacement therapy develop a complex disease
comprising partially treated uremia and ill effects of dial-
ysis, such as fluctuation in the extracellular fluid volume,
residual inorganic ion disturbances and exposure to bio-
incompatible materials [7,8].
Additionally, it is well known that during these treatments
the interaction of peripheral blood mononuclear cells
(PBMC) with bioincompatible dialysis devices causes
their activation with consequent increased synthesis and
release of pro-inflammatory cytokines [9-12], imbalance
between pro- and anti-oxidant activities resulting in high
oxidative stress [13,14] and immune system deregulation
[15]. All together these conditions may lead to severe clin-
ical complications including cardiovascular disease,
atherosclerosis, anemia and malnutrition with a conse-
quent low quality of life, high risk of hospitalization and
short survival of this patients' population [16-19].
In the last decade, numerous studies have investigated the
molecular triggers and biological key elements associated
to the development of these clinical changes, but the com-
plete picture of this process is still incomplete [20-22].
New strategies based on the combination of traditional
molecular approaches (e.g., polymerase chain reaction,
western blotting) and innovative high-throughput tech-
nologies have been proposed to address this issue. In par-
ticular, microarrays, largely employed in the screening of
complex biological events, analyzing simultaneously
thousand of genes, represent one of the most powerful
and highly sensitive tool to investigate the potential
molecular interactions and multi-factorial variables
involved in biological processes [23,24].
To date, only few studies have employed this methodol-
ogy to select the molecular fingerprints associated with
the onset and progression of renal damage and to build
models defining the mechanisms underlying severe clini-
cal complication associated to CKD and dialysis therapy
[25-27]. However, these studies have been performed on
a relatively small number of patients and on limited gene
datasets.
Therefore, the aim of the present study was to uncover,
through a combined strategy based on an innovative
high-throughput technology (microarray) and classical
molecular methodologies, the mechanisms underlying
alterations in cell metabolism featuring patients with
CKD.
Results
Microarray analysis
To identify specific genomic fingerprints differentiating
healthy subjects from those with chronic kidney disease,
we analyzed the gene-expression profiling of PBMC iso-
lated from 8 healthy subjects, 9 CKD patients on stage II–
III (CKD II–III) and 17 patients undergoing HD treatment
(HD). According to independent statistical algorithms
and the estimated FDR, we identified 49 gene probe sets
(corresponding to 44 genes) up-regulated in CKD II–III
and HD and able to discriminate the three study groups (p
< 0.001, FDR = 1%). However, we found only a slight and
not significant difference in the genomic profile between
CKD II–III and normal subjects (p < 0.06) (FIGURE 1).
The latter result may be related to the low degree of renal
failure of the CKD population included in the microarray
analysis. The 2D hierarchical clustering using the 49
selected gene probe sets showed the degree of separation
among the 3 study groups (FIGURE 1).
Functional analysis of the transcriptomic profile identified 
by microarray
Using Ingenuity Pathway Analysis (IPA) software, we
found that the top selected genes were involved in several
biological pathways including oxidative phosphorylation
system, ubiquinone biosynthesis and glucocorticoids
receptor signaling. However, oxidative phosphorylation
system, including 11 of 44 genes (ATP5O, COX6C,
COX7C, NDUFS5, NDUFA6, UQCRH, NDUFA1, ATP5J,
UQCRB, NDUFB1 and ATP5I), reached the highest level
of significance (FIGURE 2A). The relative connectivity dia-
gram in Figure 2B shows the high degree of direct and
indirect biological association (score = 30, p < 0.0001)
among the selected genes. In addition, KEGG analysis
reveals that the 11 genes encode for essential subunits of
complex I, III, IV and V of oxidative phosphorylation
pathway (FIGURE 3).
Validation of microarray using 4 representative genes of 
the oxidative phosphorylation system
COX6C, COX7C, ATP5I, and UQCRH mRNA levels, meas-
ured on the same microarray population and 10 addi-
tional CKD patients on stage IV–V, were significantlyPage 2 of 13
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healthy subjects. For all the genes analyzed there was no
statistical difference in the expression levels between CKD
IV–V and HD patients (FIGURE 4A, B, C and 4D). Only
for ATP5I and UQCRH mRNA levels there was a statisti-
cally significant difference between CKD II–III and
healthy subjects (FIGURE 4A and 4D, respectively). These
results were in line with those obtained by the microarray
analysis and indicated a possible similarity in oxidative
phosphorylation system activity between CKD IV–V and
HD patients.
COXI and COXIV protein expression
Based on the results obtained in first part of the study, sug-
gesting a significant involvement of the mitochondrial
respiratory system in patients with a high degree of renal
failure (CKD IV–V) and HD, we measured the protein
level of the mitochondrial-encoded subunit I (COXI) and
the nuclear-encoded subunit IV (COXIV) of complex IV in
the testing-group. As shown in figure 5, COXI and COXIV
levels were higher in CKD IV–V and HD compared to the
control group. However, only for COXI, the comparison
between CKD IV–V and healthy subjects reached the sta-
tistical significance. In addition, for both proteins, there
were no significant differences in expression levels
between CKD IV–V and HD patients.
Complex IV (COX) activity
To obtain additional knowledge about the mitochondrial
respiratory system function in patients with CKD, we
"Supervised" hierarchical clustering discriminating healthy subjects (HS), chronic kidney disease (CKD) and hemodialysis (HD) patientsFigure 1
"Supervised" hierarchical clustering discriminating healthy subjects (HS), chronic kidney disease (CKD) and 
hemodialysis (HD) patients. (A) Patients are depicted as vertical columns, with blue line in the bottom indicating healthy 
subjects (HS) (n = 8), green indicating (CKD II–III) (n = 9) and red indicating (HD) (n = 17) patients. Forty-nine gene probe sets 
(rows, with gene names shown) were used for hierarchical clustering. P-values were calculated by ANOVA. The relative level 
of gene expression is depicted from lowest (green) to highest (red) according to the scale shown at the top.Page 3 of 13
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Functional categorization, and Ingenuity Pathway Analysis (IPA) network of the top selected genes by microarrayigure 2
Functional categorization, and Ingenuity Pathway Analysis (IPA) network of the top selected genes by micro-
array. (A) Histogram represents the most significant canonical pathways generated using IPA software including the 44 genes 
discriminating the three study groups. Ratio was calculated by dividing the number of genes from our dataset that map to each 
single pathway by the total number of genes included into the canonical pathway. P-value was calculated using the right-tailed 
Fisher's Exact Test. Ratio and P-value are indicated on the left and right side of the histogram, respectively. (B) Network, algo-
rithmically generated based on their functional and biological connectivity, was graphically represented as nodes (genes) and 
edges (the biological relationship between genes). Shaded nodes represented genes identified by our microarray analysis and 
others (empty nodes) were those that IPA automatically included because biologically linked to our genes based on evidence in 
the literature. Red shaded genes were those involved in oxidative phosphorylation system (OXPHOS).
BMC Genomics 2009, 10:388 http://www.biomedcentral.com/1471-2164/10/388measured the Complex IV activity in 6 HD, 6 CKD
patients and 6 healthy subjects. Mean enzymatic activity
was reduced by 65% in CKD IV–V and by 46% in HD
patients compared to the control group, while no statisti-
cal difference was found in the comparison between CKD
IV–V and HD patients (FIGURE 6).
Intracellular Reactive Oxygen Species (ROS) levels
Since a significant part of ROS generation is dependent on
the mitochondrial respiratory chain activity, we measured
their levels in PBMC of all the testing-group population.
Both, CKD IV–V and HD patients have significantly
higher ROS levels compared to healthy subjects. No differ-
ences were observed between CKD IV–V and HD (FIGURE
7A).
DNA oxidative damage
We measured serum 8-hydroxydeoxyguanosine (8-
OHdG) levels in all testing-group population as an oxida-
tive stress biomarker. Both, CKD IV–V and HD patients
had significantly higher 8-OHdG levels compared to the
control group. In addition HD patients showed higher 8-
OHdG levels compared to CKD IV–V (FIGURE 7B).
Discussion
In the last twenty years, several reports have focused on
the molecular changes occurring during the onset and
progression of CKD, but this rich literature appears frag-
mented and not exhaustive [10,12,21]. Analyzing these
reports the attitude to focus on small number of biologi-
cal elements and the lack of a comprehensive strategy to
study the biochemical network associated with CKD is
evident. In addition, despite the efforts of researchers and
clinicians, CKD and renal replacement therapy are still
associated to important clinical complications. In particu-
lar, during HD, the interaction of PBMC with dialytic
membranes causes their activation with a consequent
increased synthesis and release of pro-inflammatory
KEGG pathway diagram including the 11 oxidative phosphorylation system (OXPHOS) genes selected by microarray analysisFigure 3
KEGG pathway diagram including the 11 oxidative phosphorylation system (OXPHOS) genes selected by 
microarray analysis. In the upper part are shown the five respiratory chain complexes with the corresponding E.C. num-
bers. In the bottom part, as rectangles, are indicated the subunits of each respiratory chain complex. The subunits encoded by 
genes selected by microarray analysis are shown by colored (pink shaded) rectangles.Page 5 of 13
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oxidant activities, resulting in high oxidative stress with
elevated synthesis of ROS [13,14].
In the present study, we used a whole genome analysis by
microarray technology, combined with classical biomo-
lecular approaches, to detect unrecognized biological ele-
ments deregulated in subjects with CKD and to identify
new potential targets for pharmacological interventions.
Microarray analysis revealed a specific genomic finger-
print able to identify HD and CKD patients from healthy
subjects. Functional analysis by IPA and KEGG demon-
strated that 25% of the selected genes encodes for protein
involved in mitochondrial oxidative phosphorylation sys-
tem.
Mitochondria are essential eukaryotic cells organelles
involved in several metabolic pathways, calcium and iron
homeostasis, ROS production and programmed cell death
[28]. They present an outer and inner membrane, the lat-
ter of which would be impermeable to all molecules in the
absence of specific carriers and contains the enzymatic
oxidative phosphorylation complex. The respiratory flux
is due to the donation of electrons from NAD- or FAD-
dependent substrates, via respiratory chain, to molecular
oxygen which is finally reduced to water. Simultaneously,
the energy conserving complexes I, III and IV build up a
trans-membrane electrochemical gradient by coupling the
electron transfer activity to proton translocation from the
matrix to the outer side of the inner mitochondrial mem-
ATP5I, COX6C, COX7C and UQCRH gene expression by RT-PCR in peripheral blood mononuclear cells (PBMC) from healthy subjects (HS), chronic kidney diseas (CKD II–III and CKD IV–V) and hemodialysis (HD) patientsFigure 4
ATP5I, COX6C, COX7C and UQCRH gene expression by RT-PCR in peripheral blood mononuclear cells 
(PBMC) from healthy subjects (HS), chronic kidney disease (CKD II–III and CKD IV–V) and hemodialysis (HD) 
patients. The histograms represent the mean ± SD of ATP5I (A), COX6C (B), COX7C (C) and UQCRH (D) level of expres-
sion, determined by RT-PCR, in PBMC from 8 HS, 9 CKD II–III, 10 CKD IV–V and 30 HD patients. For all 4 genes, the expres-
sion level was significantly higher in HD and CKD IV–V compared to CKD II–III and HS.Page 6 of 13
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gradient for ATP synthesis.
A significant number of the genes discriminating CKD
and HD patients from healthy subjects were involved in
the synthesis of important nuclear-encoded structural
subunits of the oxidative phosphorylation complexes. In
particular, NDUFA6, NDUFS5, NDUFA1 and NDUFB1
encode for subunits of the Complex I (NADH dehydroge-
nase) that is involved in the transfer of electrons from
NADH to ubiquinone [29]. Interestingly, another gene
encoding for a subunit of this complex (NDUFA2) was
identified by microarray analysis being up-regulated in
skeletal muscle biopsy specimens of HD patients com-
pared to control subjects without renal failure [27].
COX6C, COX7C encode for two subunits of the cyto-
chrome c oxidase (COX or Complex IV), the terminal
enzyme of the mitochondrial respiratory chain catalyzing
the electron transfer from reduced cytochrome c to oxygen
[30]. ATP5O, ATP5I and ATP5J encode for components of
the ATP synthase (complex V).
To investigate whether the increased gene expression
observed in our genomic study was, indeed, associated
with an increased oxidative phosphorylation system activ-
ity, we analyzed the protein expression of mitochondrial-
coding COXI (catalytic subunit) and nuclear-coding
COXIV subunits of Complex IV. Although these two
essential subunits of Complex IV have not been identified
by our genomic approach, we decided to measure their
COXI (A and B) and COXIV (C and D) protein expression in peripheral blood mononuclear cells (PBMC) from healthy sub-jects (HS), chronic kidney disease (CKD IV–V) and hemodialysis (HD) patientsFigure 5
COXI (A and B) and COXIV (C and D) protein expression in peripheral blood mononuclear cells (PBMC) 
from healthy subjects (HS), chronic kidney disease (CKD IV–V) and hemodialysis (HD) patients. Panel A and C 
show a representative western blotting experiment respectively for COXI and COXIV. The histograms represent the mean ± 
SD of COXI (panel B) and COXIV (panel D) protein levels in total cell lysate of 12 HS, 10 CKD IV–V and 14 HD patients 
assessed by Western blotting. COXI and COXIV protein level was significantly higher in HD and CKD compared to HS.Page 7 of 13
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trol on the respiration of a variety of human cells includ-
ing myeloma [31] and Jurkat blood cells [32]. The
observation that the expression of both proteins was
higher in HD and CKD patients compared to healthy sub-
jects further confirmed the data obtained by the microar-
ray analysis.
Additionally, when we measured the activity of complex
IV, despite the expected high interindividual variability
[33], we observed a dramatic reduction in both CKD and
HD patients compared to healthy subjects. This is in line
with experimental evidences suggesting that chronic oxi-
dative stress and oxidant injury may enhance the expres-
sion of several nuclear mitochondrial biogenesis genes
[34,35]. Indeed, our results highlight the role of oxidative
stress in this process since both CKD and HD patients
were characterized by an elevated intracellular ROS pro-
duction and a high level of 8-OHdG, a marker of oxidative
stress to DNA [36]. ROS may deeply influence a variety of
key cell functions damaging proteins, lipids and nucleic
acids [37-39] and inhibiting directly the enzymatic activi-
ties of several elements of the cellular respiratory chains
[40-42]. Thus, our hypothesis is that an increased produc-
tion of ROS due to the effect of pro-inflammatory media-
tors may cause a profound inhibition of the oxidative
phosphorylation system leading to a compensatory
"hypertrophy" of its components. In addition, a hyper-
trophic and impaired oxidative phosphorylation system
may prime a vicious circle, causing a continuous release of
ROS.
An interesting point in our study is that CKD and HD
patients are virtually undistinguishable when it comes to
the expression of oxidative phosphorylation system com-
ponents. On this basis, we may consider this finding as a
genomic hallmark of CKD itself that is not modulated by
HD treatment. However, it should be taken into consider-
ation that our HD patient's population has been treated
with highly biocompatible synthetic membranes, previ-
ously shown to cause a very limited lymphomononuclear
cell activation [43-45], although, Raj DS et al. have
reported that mitochondrial dysfunction is induced even
with the use of biocompatible membrane [46].
Conclusion
In conclusion, our results suggest, for the first time, a clear
deregulation of the mitochondrial respiratory machinery
in the CKD patients closely associated with an enhanced
oxidative stress. This may explain previous fragmented
reports indicating a subnormal energy metabolism in this
complex population. Finally, our research strategy may
delineate a new methodological approach for biologists
and clinicians who may collaborate and achieve what has
been recently termed as "translational medicine".
Methods
Patients
A total of 80 subjects, after signing informed consent
according to declaration of Helsinki, were included in the
study and divided in a training-group (n = 44) and a test-
ing-group (n = 36).
A) Training-group
This population was used for the microarray analysis and
to generate the initial genomic model. It included 8
healthy subjects, 9 CKD patients on stage II–III (mean ±
SD of estimated GFR by MDRD formula: 41.4 ± 4.3 ml/
min) and 17 HD patients. To define the influence of the
degree of renal failure on the transcriptomic profile and to
better select the population for the second part of the
study, we added 10 CKD patients on stage IV–V (mean ±
Cytochrome c oxidase (COX) activity in peripheral blood mononuclear cells (PBM ) from healthy subjects (HS), chr nic kidney di e  ( KD IV–V) and hemodialysis (HD) patie tsFigure 6
Cytochrome c oxidase (COX) activity in peripheral 
blood mononuclear cells (PBMC) from healthy sub-
jects (HS), chronic kidney disease (CKD IV–V) and 
hemodialysis (HD) patients. Dot-plot represents the 
mean ± SD of COX enzymatic activity measured by following 
the oxidation of ferrocytochrome c at 550-540 nm in total 
cell lysate of 6 HS, 6 CKD and 6 HD. Activity was signifi-
cantly lower in CKD IV–V and HD compared to HS. The line 
represents the mean value.Page 8 of 13
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min) in the RT-PCR experiments.
B) Testing-group
This population was used to confirm the hypothesis gen-
erated by the training-group and it included 12 healthy
subjects, 10 CKD IV–V (mean ± SD of estimated GFR by
MDRD formula: 20.2 ± 3.7 ml/min) and 14 HD patients.
In this part of the study, we did not include CKD patients
on stage II–III based on the results obtained in the train-
ing-group showing only a slight difference in gene expres-
sion between this group and the control group.
All HD patients were stably treated, for at least 1 year,
three times a week (4–5 hours per session), using syn-
thetic membrane dialyzers. During the study period, no
CKD patients received dialysis treatment. In addition, all
patients suffering from infectious diseases, diabetes,
chronic lung diseases, neoplasm, or inflammatory dis-
eases and patients receiving antibiotics, corticosteroids, or
non-steroidal anti-inflammatory agents were excluded.
No patients had symptomatic coronary artery diseases or
a family history of premature cardiovascular diseases. The
main clinical and demographic characteristics of the sub-
jects included in the training and testing group are sum-
marized in TABLE 1 and 2, respectively.
PBMC isolation
Twenty ml of whole blood were collected from all subjects
included in both training- and testing-group. For HD
patient the biological material was obtained at the begin-
ning of the second HD session of the week. PBMC were
isolated by density separation over a Ficoll-Paque™ (GE
healthcare, Sweden) gradient (460 g for 30 min). PBMC
were washed three times with PBS pH 7.4/1 mM EDTA
(Sigma, Milan, Italy). Cells were then counted and their
viability was assessed by trypan blue exclusion (>90%
PBMC were viable).
RNA extraction and gene expression profiling
For all subjects included in the training-group, total RNA
was isolated by RNeasy mini kit Qiagen (QIAGEN AG,
Basel, Switzerland) from a minimum of 5 × 106 cryopre-
served PBMC. RNA was, then, processed and hybridized
to the GeneChip Human Genome U133 oligonucleotide
microarray (n = 5 to the HG-U133-Plus and n = 29 to the
HG-U133A array). For our analysis, we used a dataset
including 22,283 gene probe sets, representing 12,357
human genes and 3,800 ESTs (Affymetrix; see the manu-
facturer's manual for detailed protocol). We used the
default settings of Affymetrix Microarray Suite software
version 5 to calculate scaled gene expression values.
Results of the microarray experiments are available in
Intracellular reactive oxygen species (ROS) and serum 8-hydroxydeoxyguanosine (8-OHdG) levels in healthy subjects (HS), chronic kidney disease (CKD IV–V) and hemo ialysis (HD) patientsFigur 7
Intracellular reactive oxygen species (ROS) and serum 8-hydroxydeoxyguanosine (8-OHdG) levels in healthy 
subjects (HS), chronic kidney disease (CKD IV–V) and hemodialysis (HD) patients. The histograms represent the 
mean ± SD of 2',7'-Dichlorodihydrofluorescein (DCF) fluorescence (A) and serum 8-OHdG levels (B) in 12 HS, 10 CKD and 
14 HD patients. DCF fluorescence in PBMC, reflecting the relative ROS levels, and the serum 8-OHdG levels were higher in 
HD and CKD compared to HS. In addition HD patients had higher 8-OHdG levels compared to CKD.Page 9 of 13
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GSE15072).
Reverse transcription-polymerase chain reaction (RT-
PCR)
Reverse transcription of RNA was performed using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), following the manufacture's instructions.
One μg of RNA was reverse transcribed using random
primer and MultiScribe Reverse Transcriptase. All amplifi-
cation reactions were performed using primer designed by
the aid of the Primer3 software (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3.cgi). For COX6C mRNA expres-
sion, the primer sequences were: forward 5'-ctttgtataagtt-
tcgtgtgg-3' and reverse 5'-attcatgtgtcatagttcagg-3'. The
conditions of amplification were: 94°C for 20 sec, 58°C
for 20 sec, 70°C for 20 sec for a total of 35 cycles of ampli-
fication. The primers used for COX7C were forward 5'-
ccctgggaagaatttgcca-3' and reverse 5'-ggaactgaaacatccttatg-
3'. The conditions of amplification were: 94°C for 20 sec,
56°C for 20 sec, 70°C for 20 sec for a total of 30 cycles of
amplification. The primers used for ATP5I were forward
5'-cgctacaattacctaaaacctc-3' and reverse 5'-ctttattcatccgct-
gctggt-3'. The conditions of amplification were: 94°C for
20 sec, 60°C for 20 sec, 70°C for 20 sec for a total of 30
cycles of amplification. The primers used for UQCRH
were forward 5'-agggaccattgcgtggcc-3' and reverse 5'-
agctaccagcctaagccaaa-3'. The conditions of amplification
were: 94°C for 20 sec, 58°C for 20 sec, 70°C for 20 sec for
a total of 30 cycles of amplification. β-actin PCR products
were used as control gene. β-actin primer sequences were
forward 5'-ggcatcgtgatggactccg-3' and reverse 5'-gctggaag-
gtggacagcga-3'. The conditions of amplification were:
94°C for 20 sec, 65°C for 20 sec, 70°C for 20 sec for a
total of 30 cycles of amplification. PCR products were
electrophoretically separated on agarose gels and stained
with ethidium bromide. The density of each band, corre-
sponding to a specific PCR product, was densitometrically
quantified by pixel density using NIH Image J image soft-
ware http://rsb.info.nih.gov/ij/. The ratio between
COX6C, COX7C, ATP5I, UQCRH and β-actin PCR prod-
ucts were used as indexes of COX6C, COX7C, ATP5I,
UQCRH gene expression.
Western blot analysis
For western blots, equal amounts of total cellular proteins
(10–20 μg) extracted by PBMC isolated from all patients
included in the testing-group, were separated on a 13%
SDS-polyacrylamide gel and transferred onto nitrocellu-
lose membrane. Membranes were then blocked with 5%
non-fat milk in 0.1% TBS-Tween-20 and probed with spe-
cific antibodies against the mitochondrial-encoded subu-
nit I (COXI gene, Molecular Probes, Eugene, OR) and the
nuclear-encoded subunit IV (COXIV, Molecular Probes)
of respiratory complex IV. Membranes were also probed
with specific antibody against actin (from Sigma) utilized
as loading control. Membranes were finally incubated
with HRP-conjugated secondary antibodies and devel-
oped with Immune-Star HRP chemiluminescent kit (Bio-
Rad). The specific COXI and COX IV bands were quanti-
fied by pixel density using NIH ImageJ image software and
normalized to the actin band.
Assessment of COX IV activity
PBMC, isolated by 6 HD, 6 CKD IV–V and 6 healthy sub-
jects, were resuspended in hypotonic medium (25 mM
potassium phosphate pH 7.4, 5 mM MgCl2) and supple-
mented with a protease inhibitors cocktail (Roche Diag-
nostics, Mannheim, Germany). In order to allow
complete accessibility of substrates to the inner mitochon-
drial membrane enzymes, samples were freeze-thawed
three times. Protein concentration was determined
according to Bradford method, using BSA as standard. The
enzyme activity was measured at 30°C using 0.03–0.1
Table 1: Patient demographics and clinical characteristics of the training-group
healthy subjects CKD II–III CKD IV–V HD P-value
Number 8 9 10 17 /
Gender (M/F) 3/5 5/4 6/4 10/7 n.s.
Age (years) 49.37 ± 10.68 49.12 ± 9.82 51.11 ± 7.18 52.86 ± 8.63 n.s.
Cause of CKD: GN, ADPKD, renal vascular disease, unknown / 3,2,1,3 4,2,2,2 6,4,2,5 n.s.
Time on dialysis (years) / / / 3.98 ± 0.56 /
BMI (kg/m2) 22.9 ± 1.42 22.1 ± 0.92 21.3 ± 1.05 21.8 ± 1.01 p = 0.02
Systolic blood pressure (mmHg) 121 ± 3.51 135 ± 17.4 137 ± 13.22 136 ± 13.22 p = 0.05
Diastolyc blood pressure (mmHg) 72.12 ± 7.59 83.11 ± 6.23 82 ± 9.54 84 ± 10.01 p = 0.02
Total protein (g/dl) 7.02 ± 0.31 6.60 ± 0.42 5.82 ± 0.72 5.96 ± 0.36 p < 0.01
Albumin (g/dl) 4.4 ± 0.11 4.1 ± 0.24 3.93 ± 0.67 3.48 ± 0.51 p < 0.01
Ferritin (ng/ml) 87 ± 40.1 136 ± 56.1 376 ± 318.2 451 ± 283.1 p < 0.01
Hemoglobin (g/dl) 13.65 ± 1.17 12.07 ± 1.70 11.13 ± 1.01 11.48 ± 1.98 p < 0.01
GN: Glomerulonephritis; ADPKD: Autosomal dominant polycystic kidney disease. Values are expressed as mean ± SD. P-values calculated by 
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spectrophotometer equipped with a rapid-mixing appara-
tus, essentially as previously described [47].
The KCN-sensitive cytochrome c oxidase (complex IV)
activity was measured by following the initial rate of oxi-
dation of ferrocytochrome c (20 μM) at 550-540 nm (Δε
= 19.1 mM-1cm-1).
Measurement of intracellular ROS production
For all patients included in the testing-group, peroxide-
sensitive fluorescent probe 2',7'-dichlorodihydrofluo-
rescin diacetate (Molecular Probes) was used to assess the
generation of intracellular peroxide (hydrogen peroxide
and peroxynitrite) as previously described [48]. This com-
pound is converted by intracellular esterases to 2',7'-
dichlorodihydrofluorescein, which is then oxidized by
hydrogen peroxide to the highly fluorescent 2',7'-dichlo-
rodihydrofluorescein (DCF). PBMC were maintained in
culture medium (RPMI-1640, Sigma, Milan, Italy) supple-
mented with 10% fetal bovine serum (FBS), 1% penicil-
lin-streptomycin, 2 mM L-glutamine for 24 hours. The
cells were, then, washed with Hank's balanced salt solu-
tion (HBSS) without phenol red and incubated with 5 μM
2',7'-dichlorodihydrofluorescin diacetate in the dark for
20 min at 37°C. Subsequently, DCF fluorescence was
detected at excitation and emission wavelengths of 488
nm and 520 nm, respectively, and measured with a fluo-
rescence reader (JASCO-FP-6200).
8-OHdG assay
Serum 8-OHdG levels were measured with a competitive
enzyme-linked immunosorbent assay kit (high sensitivity
8-OhdG Check; Japan Institute for the Control of Aging,
Shizuoka, Japan) in all subjects included in the testing-
group. Briefly, 50 μl of sample and 8-OHdG monoclonal
antibody were added to each well and incubated at 4°C
overnight. After washing, horseradish peroxidase-conju-
gated antibody was added to the plate and incubated for
60 min. The plate was washed again and 100 μl of enzyme
substrate was added to each well and incubate at room
temperature for 15 minutes. After terminating the reac-
tion the absorbance was read at 450 nm.
Statistical analysis
Results were expressed as mean ± SD. t-test, ANOVA and
Fisher's exact test were used to assess differences in clinical
and demographic features. A value of P < 0.05 was consid-
ered to be statistically significant.
For microarray analysis, gene expression values for the
22,283 gene probe sets, scaled to the target intensity of
2,500, were log transformed. ANOVA and permutation
analysis by Storey's q-value [49] were used to identify gene
probe sets discriminating CKD and HD patients from
healthy subjects. However, to better select genes deregu-
lated in patients with advanced renal failure and to reduce
the number of variables to include in the second part of
the study, we decided to focus our attention on the top up-
regulated gene probe sets in HD patients. R 2.0.1 statisti-
cal software was used to perform the above analyses. Hier-
archical clustering was build using Spotfire DecisionSite
9.0 http://www.spotfire.com.
To assess the biological relationships among genes, we
used the Ingenuity Pathway Analysis software (IPA, Inge-
nuity System, Redwood City, CA; http://www.ingenu
ity.com) and the Kyoto Encyclopedia of Genes and
Genomes (KEGG, http://www.genome.ad.jp/kegg/). IPA
is a knowledge database generated from the peer-reviewed
scientific publications that enables discovery, visualiza-
tion and exploration of functional biological networks in
gene expression data and delineates the functions most
significant to those networks. A score is assigned to each
generated network according to the number of differen-
tially regulated focus genes in our dataset. These scores are
Table 2: Patient demographics and clinical characteristics of the testing-group
healthy subjects CKD IV–V HD P-value
Number 12 10 14 /
Gender (M/F) 7/5 6/4 8/6 n.s.
Age (years) 50.78 ± 10.45 51.64 ± 10.26 52.86 ± 8.63 n.s.
Cause of CKD: GN, ADPKD, renal vascular disease, unknown / 4,2,2,2 5,3,1,5 n.s.
Time on dialysis (years) / / 3.98 ± 0.56 /
BMI (kg/m2) 23.1 ± 0.82 21.9 ± 0.74 22.1 ± 1.01 p < 0.01
Systolic blood pressure (mmHg) 120 ± 4.01 136 ± 9.71 138 ± 8.11 p < 0.01
Diastolyc blood pressure (mmHg) 74.36 ± 5.31 82.1 ± 10.03 88 ± 10.86 p < 0.01
Total protein (g/dl) 6.98 ± 0.41 5.98 ± 0.76 6.02 ± 0.31 p < 0.01
Albumin (g/dl) 4.3 ± 0.31 3.71 ± 0.42 3.48 ± 0.51 p < 0.01
Ferritin (ng/ml) 79 ± 62.3 210 ± 183.6 451 ± 283.1 p < 0.001
Hemoglobin (g/dl) 13.46 ± 1.62 11.88 ± 1.87 11.48 ± 1.98 p < 0.01
GN: Glomerulonephritis; ADPKD: Autosomal dominant polycystic kidney disease. Values are expressed as mean ± SD. P-values calculated by 
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BMC Genomics 2009, 10:388 http://www.biomedcentral.com/1471-2164/10/388derived from negative logarithm of the P indicative of the
likelihood that focus genes found together in a network
due to random chance. Scores of 4 or higher have 99.9%
confidence level of significance. KEGG is a collection of
online databases dealing with genome, enzymatic path-
ways and biological chemicals. KEGG connects known
information on molecular interaction networks, such as
pathways and complexes, about genes and proteins gener-
ated by genome projects and biochemical compounds
and reactions.
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